Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:29:49 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:MESO from 2023-04-30 to 2024-04-29 - 20 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-25 22:34U:MESONews ReleaseUnited States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
2024-03-13 19:31U:MESONews ReleaseMesoblast Successfully Completes Placement and Accelerated Entitlement Offer
2024-03-10 19:54U:MESONews ReleaseUnited States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
2024-02-28 17:57U:MESONews ReleaseMesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
2024-02-26 07:00U:MESONews ReleaseMesoblast Financial Results and Corporate Update Webcast
2024-02-14 19:47U:MESONews ReleaseUnited States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor ‚ ® (Rexlemestrocel-L) in Children With Congenital Heart Disease
2024-01-30 21:14U:MESONews ReleaseAppendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
2024-01-18 18:36U:MESONews ReleaseUnited States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor ‚ ® (Rexlemestrocel-L) in Children With Congenital Heart Disease
2023-11-26 18:56U:MESONews ReleaseMesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
2023-11-21 18:32U:MESONews ReleaseMesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
2023-10-30 20:04U:MESONews ReleaseAppendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
2023-09-26 06:19U:MESONews ReleaseJane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
2023-09-21 03:31U:MESONews ReleaseKey Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
2023-08-30 19:07U:MESONews ReleaseMesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
2023-08-29 07:00U:MESONews ReleaseMesoblast Financial Results and Corporate Update Webcast
2023-08-03 20:11U:MESONews ReleaseMesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
2023-07-30 20:31U:MESONews ReleaseAppendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
2023-06-04 20:22U:MESONews ReleaseMesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
2023-05-25 19:29U:MESONews ReleaseMesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
2023-05-24 07:00U:MESONews ReleaseMesoblast Financial Results and Corporate Update Webcast